Loading clinical trials...

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT01783834

Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

Lead sponsor: Gachon University Gil Medical Center•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment95

Start dateFeb 2008

Last updatedFeb 11, 2016

Condition

Previous Treated Metastatic Non-small Cell Lung Cancer

Locations shown

Gachon university Gil Medical Center

Incheon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2016Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions